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Wolfram syndrome is a genetic disorder characterized by diabetes
and neurodegeneration and considered as an endoplasmic re-
ticulum (ER) disease. Despite the underlying importance of ER
dysfunction in Wolfram syndrome and the identification of two
causative genes, Wolfram syndrome 1 (WFS1) and Wolfram syn-
drome 2 (WFS2), a molecular mechanism linking the ER to death
of neurons and β cells has not been elucidated. Here we implicate
calpain 2 in the mechanism of cell death in Wolfram syndrome.
Calpain 2 is negatively regulated by WFS2, and elevated activation
of calpain 2 byWFS2-knockdown correlates with cell death. Calpain
activation is also induced by high cytosolic calciummediated by the
loss of function of WFS1. Calpain hyperactivation is observed in the
WFS1 knockout mouse as well as in neural progenitor cells derived
from induced pluripotent stem (iPS) cells of Wolfram syndrome
patients. A small-scale small-molecule screen targeting ER calcium
homeostasis reveals that dantrolene can prevent cell death in neu-
ral progenitor cells derived from Wolfram syndrome iPS cells. Our
results demonstrate that calpain and the pathway leading its acti-
vation provides potential therapeutic targets for Wolfram syn-
drome and other ER diseases.
Wolfram syndrome | endoplasmic reticulum | diabetes |
neurodegeneration | treatment
The endoplasmic reticulum (ER) takes center stage for proteinproduction, redox regulation, calcium homeostasis, and cell
death (1, 2). It follows that genetic or acquired ER dysfunction
can trigger a variety of common diseases, including neurodegen-
erative diseases, metabolic disorders, and inflammatory bowel
disease (3, 4). Breakdown in ER function is also associated with
genetic disorders such as Wolfram syndrome (5–8). It is chal-
lenging to determine the exact effects of ER dysfunction on the
fate of affected cells in common diseases with polygenic and
multifactorial etiologies. In contrast, we reasoned that it should
be possible to define the role of ER dysfunction in mechanisti-
cally homogenous patient populations, especially in rare diseases
with a monogenic basis, such as Wolfram syndrome (9).
Wolfram syndrome (OMIM 222300) is a rare autosomal re-
cessive disorder characterized by juvenile-onset diabetes mellitus
and bilateral optic atrophy (7). Insulin-dependent diabetes usu-
ally occurs as the initial manifestation during the first decade of
life, whereas the diagnosis of Wolfram syndrome is invariably
later, with onset of symptoms in the second and ensuing decades
(7, 10, 11). Two causative genes for this genetic disorder have
been identified and named Wolfram syndrome 1 (WFS1) and
Wolfram syndrome 2 (WFS2) (12, 13). It has been shown that
multiple mutations in the WFS1 gene, as well as a specific muta-
tion in theWFS2 gene, lead to β cell death and neurodegeneration
through ER and mitochondrial dysfunction (5, 6, 14–16). WFS1
gene variants are also associated with a risk of type 2 diabetes (17).
Moreover, a specificWFS1 variant can cause autosomal dominant
diabetes (18), raising the possibility that this rare disorder is rel-
evant to common molecular mechanisms altered in diabetes and
other human chronic diseases in which ER dysfunction is involved.
Despite the underlying importance of ER malfunction in
Wolfram syndrome, and the identification of WFS1 and WFS2
genes, a molecular mechanism linking the ER to death of neu-
rons and β cells has not been elucidated. Here we show that the
calpain protease provides a mechanistic link between the ER and
death of neurons and β cells in Wolfram syndrome.
Results
The causative genes for Wolfram syndrome, WFS1 and WFS2,
encode transmembrane proteins localized to the ER (5, 12, 13).
Mutations in the WFS1 or WFS2 have been shown to induce
neuronal and β cell death. To determine the cell death pathways
emanating from the ER, we sought proteins associated with
Wolfram syndrome causative gene products. HEK293 cells were
transfected with a GST-tagged WFS2 expression plasmid. The
GST-WFS2 protein was purified along with associated proteins
on a glutathione affinity resin. These proteins were separated by
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SDS/PAGE and visualized by Coomassie staining. Matrix-assisted
laser desorption/ionization-time of flight (MALDI-TOF) mass
spectroscopic analysis revealed 13 interacting proteins (Table S1),
and one of the WFS2-associated polypeptides was CAPN2, the
catalytic subunit of calpain 2, a member of the calcium dependent
cysteine proteases family whose members mediate diverse biological
functions including cell death (19–21) (Fig. 1A). Previous studies
have shown that calpain 2 activation is regulated on the ER
membrane and it plays a role in ER stress-induced apoptosis and β
cell death (20, 22–24), which prompted us to study the role of WFS2
in calpain 2 activation.
Calpain 2 is a heterodimer consisting the CAPN2 catalytic sub-
unit and the CAPNS1 (previously known as CAPN4) regulatory
subunit. We first verified that WFS2 interacts with calpain 2 by
showing that endogenous calpain 2 subunits CAPN2 (Fig. 1B) and
CAPNS1 (Fig. 1C) each associated with GST-tagged WFS2 ex-
pressed in HEK293 cells. Endogenous CAPN2 was also found
to be coimmunoprecipated with N- or C-terminal FLAG-tagged
WFS2 expressed in HEK293 cells (Fig. S1 A and B, respectively).
To further confirm these findings, we performed a coimmuno-
precipitation experiment in Neuro2a cells (a mouse neuroblas-
toma cell line) and INS-1 832/13 cells (a rat pancreatic β cell line)
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Fig. 1. WFS2 interacts with CAPN2. (A) Affinity purification ofWFS2-associated proteins from HEK293 cells transfected with GST or GST-WFS2 expression plasmid.
Proteins were separated by SDS/PAGE and visualized by Coomassie blue staining. CAPN2 was identified by MALDI-TOF analysis and denoted by an arrow. (B) GST-
tagged WFS2 was pulled down on a glutathione affinity resin from lysates of HEK293 cells transfected with a GST-WFS2 expression plasmid, and the pulled-down
products were analyzed for CAPN2 by immunoblotting with anti-CAPN2 antibody. (C) GST-tagged WFS2 was pulled down on a glutathione affinity resin from
lysates of HEK293 cells transfected with GST-WFS2 expression plasmid and the pulled-down products were analyzed for CAPNS1 by immunoblotting with anti-
CAPNS1 antibody. (D) Lysates of Neuro2a cells were immunoprecipitated with IgG or anti-calpain 2 antibodies. Lysates of IgG and anti-calpain 2 immunopre-
cipitates were analyzed for WFS2, CAPN2 or actin by immunoblotting. (E) Lysates of INS-1 832/13 cells were immunoprecipitated with IgG or anti-calpain 2
antibody. Lysates of IgG and anti-calpain 2 immunoprecipitates were analyzed for WFS2, CAPN2 or actin by immunoblotting. (F) COS7 cells were transfected with
pDsRed2-ER vector (Center) and stained with anti-calpain 2 antibody (Left). (Right) A merged image is shown. (G) HEK293 cells were transfected with empty
expression plasmid or a CAPN2 expression plasmid. Apoptosis was monitored by immunoblotting analysis of caspase 3 cleavage. (Left) Expression levels of CAPN2
and actin were measured by immunoblotting. (Right) Quantification of immunoblot is shown (n = 3, *P < 0.05).
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and found that endogenous WFS2 interacted with endogenous
CAPN2 (Fig. 1 D and E). WFS2 is known to be a transmembrane
protein localized to the ER. We therefore explored the possibility
that calpain 2 might also localize to the ER. We transfected COS7
cells with pDsRed2-ER vector to visualize ER. Immunofluores-
cence staining of COS7 cells showed that endogenous calpain 2
was mainly localized to the cytosol, but also showed that a small
portion colocalized with DsRed2-ER protein at the ER (Fig. 1F).
Cell fractionation followed by immunoblot further confirmed this
observation (Fig. S1C). Collectively, these results suggest that
calpain 2 interacts with WFS2 at the cytosolic face of the ER.
Calpain hyperactivation has been shown to contribute to cell loss
in various diseases (19), raising the possibility that calpain 2 might
be involved in the regulation of cell death. To verify this issue, we
overexpressed CAPN2, the catalytic subunit of calpain 2, and ob-
served increase of cleaved caspase-3 in HEK293 cells indicating that
hyperactivation of calpain 2 induces cell death (Fig. 1G).
To determine whether WFS2 plays a role in cell survival, we
suppressed WFS2 expression in mouse neuronal NSC34 cells using
siRNA and measured cell death under normal and ER stress
conditions. WFS2 knockdown was associated with increased
cleavage of caspase-3 in normal or ER stressed conditions (Fig. 2 A
and B). We subsequently evaluated calpain 2 activation by mea-
suring the cleavage of alpha II spectrin, a substrate for calpain 2.
RNAi-mediated knockdown of WFS2 induced calpain activation,
especially under ER stress conditions (Fig. 2A).
In patients with Wolfram syndrome, destruction of β cells
leads to juvenile-onset diabetes (25). This finding prompted us to
examine whether WFS2 was also involved in pancreatic β cell
death. As was seen in neuronal cells, knockdown of WFS2 in
rodent β cell lines INS1 832/13 (Fig. 2C) and MIN6 (Fig. S2) was
also associated with increased caspase-3 cleavage under both
normal and ER stress conditions. The association of WFS2 with
calpain 2 and their involvement in cell viability suggested that
calpain 2 activation might be the cause of cell death in WFS2-
deficient cells. To further explore the relationship between WFS2
and calpain 2, we expressed WFS2 together with the calpain 2
catalytic subunit CAPN2 and measured apoptosis. Ectopic ex-
pression of WFS2 significantly suppressed calpain 2-associated
apoptosis under normal and ER stress conditions (Fig. 2D, lane 4
and lane 8, and Fig. 2E). Next, we tested whether CAPN2
mediates cell death induced by WFS2 deficiency. When CAPN2
was silenced in WFS2-deficient cells, apoptosis was partially sup-
pressed compared with untreated WFS2-deficient cells (Fig. 2F).
Taken together, these results suggest that WFS2 is a negative
regulator of calpain 2 proapoptotic functions.
To further confirm that loss of function of WFS2 leads to cell
death mediated by calpain 2, we tested if calpeptin, a calpain in-
hibitor, could prevent cell death in WFS2-deficient cells. In agree-
ment with previous observations, calpeptin treatment prevented
WFS2-knockdown-mediated cell death in neuronal (Fig. 3 A and B)
and β cell lines (Fig. 3C and Fig. S3A). Collectively, these results
indicate that WFS2 is a suppressor of calpain 2-mediated cell death.
CAPN2 is the catalytic subunit of calpain 2. CAPN2 forms
a heterodimer with the regulatory subunit, CAPNS1, which is
required for protease activity and stability. We next explored the
role of WFS2 in CAPN2 and CAPNS1 protein stability. Ectopic
expression or RNAi-mediated knockdown of WFS2 did not
correlate with changes in the steady-state expression of CAPN2
(Fig. S3B). By contrast, overexpression of WFS2 significantly
reduced CAPNS1 protein expression (Fig. 3D) and transient
suppression of WFS2 slightly increased CAPNS1 protein ex-
pression (Fig. 3D). These data suggest that WFS2 might be in-
volved in CAPNS1 protein turnover, which is supported by the
data showing that GST-tagged WFS2 expressed in HEK293 cells
associated with endogenous CAPNS1 (Fig. 1C). To investigate
whether WFS2 regulates CAPNS1 stability through the ubiq-
uitin-proteasome pathway, we treated HEK293 cells ectopically
expressing WFS2 with a proteasome inhibitor, MG132, and then
measured CAPNS1 protein level. MG132 treatment stabilized
CAPNS1 protein in cells ectopically expressing WFS2 (Fig. 3E).
Furthermore, we performed cycloheximide chase experiments
using HEK293 cells ectopically expressing WFS2 and quantified
CAPNS1 protein levels at different time points. Ectopic expression
of WFS2 was associated with significantly accelerated CAPNS1
protein loss, indicating that WFS2 contributes to posttranslational
regulation of CAPNS1 (Fig. 3F). To further assess whether WFS2
is involved in the ubiquitination of CAPNS1, we measured the
levels of CAPNS1 ubiquitination in cells ectopically expressing
WFS2 and observed that CAPNS1 ubiquitination was increased by
ectopic expression of WFS2 (Fig. 3G).
To further investigate the role of WFS2 in calpain 2 regulation,
we collected brain lysates from WFS2 knockout mice. Measured
levels of cleaved spectrin, a well characterized substrate for cal-
pain (26). Notably, protein expression levels of cleaved spectrin,
as well as CAPNS1, were significantly increased in WFS2
knockout mice compared with control mice (Fig. 3H). Collec-
tively, these results indicate that WFS2 inhibits calpain 2 activation
by regulating CAPNS1 degradation mediated by the ubiquitin-
proteasome system.
Calpain 2 is a calcium-dependent protease. WFS1, the other
causative gene for Wolfram syndrome, has been shown to be
involved in calcium homeostasis (27, 28), suggesting that the loss
of function of WFS1 may also cause calpain activation. To
evaluate this possibility, we measured calpain activation levels in
brain tissues from WFS1 brain-specific knockout and control
mice. We observed a significant increase in a calpain-specific
spectrin cleavage product, reflecting higher calpain activation
levels in WFS1 knockout mice compared with control mice (Fig.
4A). The suppression levels of WFS1 in different parts of the
brain were shown in Fig. 4B. To further confirm that calpain is
activated by the loss of WFS1, we looked for other calpain
substrates in brain tissues from WFS1 knockout mice using
a proteomics approach. Two-dimensional fluorescence gel elec-
trophoresis identified 12 proteins differentially expressed be-
tween cerebellums of WFS1 knockout mice and those of control
mice (Fig. 4 C and D). Among these, myelin basic protein (MBP)
is a known substrate for calpain in the brain (29). We measured
myelin basic protein levels in brain lysates from WFS1 knockout
and control mice. Indeed, the cleavage and degradation of my-
elin basic protein was increased in WFS1 knockout mice relative
to control mice (Fig. 4E).
Next, we looked for evidence of increased calpain activity in
Wolfram syndrome patient cells. We created neural progenitor
cells derived from induced pluripotent stem cells (iPSCs) of
Wolfram syndrome patients with mutations inWFS1. Fibroblasts
from four unaffected controls and five patients with Wolfram
syndrome were transduced with four reprogramming genes
(Sox2, Oct4, c-Myc, and Klf4) (30) (Table S2). We produced at
least 10 iPSC clones from each control and Wolfram patient. All
control- and Wolfram-iPSCs, exhibited characteristic human
embryonic stem cell morphology, expressed pluripotency mark-
ers including ALP, NANOG, SOX2, SSEA4, TRA-1–81, and
had a normal karyotype (Fig. 5 A–F). To create neural pro-
genitor cells, we first formed neural aggregates from iPSCs.
Neural aggregates were harvested at day 5, replated onto new
plates to give rise to colonies containing neural rosette struc-
tures. At day 12, neural rosette clusters were collected, replated,
and used as neural progenitor cells. Consistent with the data
from WFS1 and WFS2 knockout mice, we observed that spectrin
cleavage was increased in neural progenitor cells derived from
Wolfram-iPSCs relative to control iPSCs, which indicates in-
creased calpain activity (Fig. 5G).
Because calpain is known to be activated by high calcium, we
explored the possibility that cytoplasmic calcium may be increased
in patient cells by staining neural progenitor cells derived from
E5294 | www.pnas.org/cgi/doi/10.1073/pnas.1421055111 Lu et al.
control- and Wolfram-iPSCs with Fura-2, a fluorescent calcium
indicator which enables accurate measurements of cytoplasmic
calcium concentrations. Fig. 5H, Left, shows that cytoplasmic cal-
cium levels were higher in Wolfram-iPSC-derived neuronal cells
relative to control cells. This result was confirmed by staining these
cells with another fluorescent calcium indicator, Fluo-4 (Fig. 5H,
Right). Collectively, these results indicate that loss of function of
WFS1 increases cytoplasmic calcium levels, leading to calpain
activation.
The results shown above argue that the pathway leading to
calpain activation provides potential therapeutic targets for
Wolfram syndrome. To test this concept, we elected to focus on
modulating cytosolic calcium and performed a small-scale screen
to identify chemical compounds that could prevent cell death
mediated by thapsigargin, a known inhibitor for ER calcium
ATPase. Among 73 well characterized chemical compounds that
we tested (Table S3), 8 could significantly suppress thapsigargin-
mediated cell death. These were PARP inhibitor, dantrolene,
NS398, pioglitazone, calpain inhibitor III, docosahexaenoic acid
(DHA), rapamycin, and GLP-1 (Fig. 6A). GLP-1, pioglitazone, and
rapamycin are FDA-approved drugs and have been shown to confer
protection against ER stress-mediated cell death (27, 31–33).
Dantrolene is another FDA-approved drug clinically used for
muscle spasticity and malignant hyperthermia (34). Previous studies
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Fig. 2. WFS2 suppresses cell death mediated by CAPN2. (A) NSC34 cells were transfected with control scrambled siRNA or siRNA directed against WFS2, and then
treated with 0.5μM thapsigargin (TG) for 6 h or untreated (UT). Apoptosis was monitored by immunoblotting analysis of cleaved caspase 3. (Left) Protein levels of
cleaved spectrin, WFS2, and actin were measured by immunoblotting. (Right) Quantifications of cleaved spectrin and cleaved caspase 3 are shown (n = 5, *P < 0.05).
(B) NSC34 cells were transfected with control scrambled siRNA or siRNA directed against WFS2, and then treated with 0.5 μM thapsigargin (TG) for 6 h or untreated
(UT). Apoptosis was monitored by Annexin V staining followed by flow cytometry analysis. (n = 3, *P < 0.05). (C) INS-1 832/13 cells were transfected with control
scrambled siRNA or siRNA directed against WFS2, and then treated with 0.5 μM thapsigargin (TG) for 6 h or untreated (UT). (Left) Expression levels of cleaved
caspase 3, WFS2, and actin were measured by immunoblotting. (Right) Protein levels of cleaved caspase 3 are quantified (n = 3, *P < 0.05). (D) NSC34 cells were
transfected with empty expression plasmid (Mock), WFS2 expression plasmid, CAPN2 expression plasmid or cotransfected with WFS1 and CAPN2 expression plas-
mids. Twenty-four h post transfection, cells were treated with 5 μg/mL tunicamycin (TM) for 16 h or untreated (UT). Apoptosis was monitored by immunoblotting
analysis of the relative levels of cleaved caspase 3 (indicated in Left). Expression levels of CAPN2, WFS2, and actin were also measured by immunoblotting.
Quantification of cleaved caspase 3 levels under untreated (Center) and tunicamycin treated (Right) conditions are shown as bar graphs. (n = 5, *P < 0.05). (E)
Neuro2a cells transfected with empty expression plasmid (Mock), WFS2 expression plasmid, CAPN2 expression plasmid or cotransfected with WFS1 and CAPN2
expression plasmids were examined for apoptosis by Annexin V staining followed by flow cytometry analysis (Right, n = 3, *P < 0.05). (F) NSC34 cells were
transfected with scrambled siRNA (Cont), WFS2 siRNA, CAPN2 siRNA or cotransfected with WFS2 siRNA and CAPN2 siRNA. Apoptosis was detected by immuno-
blotting of cleaved caspase 3. (Left) Protein levels of CAPN2, WFS2 and actin were also shown. (Right) Quantification of immunoblotting is shown (n = 3, *P < 0.05).
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have shown that dantrolene is an inhibitor of the ER-localized
ryanodine receptors and suppresses leakage of calcium from the
ER to cytosol (35, 36). We thus hypothesized that dantrolene
could confer protection against cell death in Wolfram syndrome,
and performed a series of experiments to investigate this possi-
bility. We first examined whether dantrolene could decrease cy-
toplasmic calcium levels. As expected, dantrolene treatment de-
creased cytosolic calcium levels in INS-1 832/13 and NSC34
cells (Fig. S4 A and B). We next asked whether dantrolene could
restore cytosolic calcium levels in WFS1-deficient cells. RNAi-
mediated WFS1 knockdown increased cytosolic calcium levels
relative to control cells, and dantrolene treatment restored cyto-
solic calcium levels in WFS1-knockdown INS-1 832/13 cells (Fig.
6B, Left) as well as WFS1-knockdown NSC34 cells (Fig. 6B, Right).
Next, to determine whether dantrolene confered protection in
WFS1-deficient cells, we treated WFS1 silenced INS-1 832/13 cells
with dantrolene and observed suppression of apoptosis (Fig. 6C)
and calpain activity (Fig. 6D). Dantrolene treatment also prevented
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Fig. 3. WFS2 regulates calpain activity through CAPNS1. (A) Neuro-2a cells were transfected with siRNA against WFS2 or a control scrambled siRNA. Thirty-six h after
transfection, cells were treated with or without 100μM calpeptin for 12 h. Cleaved caspase 3 and actin levels were assessed by immunoblotting (left panel). Cleaved
caspase 3 protein levels are quantified in the right panel (n = 3, *P < 0.05). (B) Neuro-2a cells were transfected with siRNA againstWFS2 or scrambled siRNA. Thirty-six h
after transfection, cells were treated with or without 100 μM calpeptin for 12 h. Early stage apoptosis was monitored by Annexin V staining followed by flow
cytometry (n = 3, *P < 0.05). (C) INS-1 832/13 cells were transfected with scrambled siRNA andWFS2 siRNA. Twenty-four h after transfection, cells were treated with or
without 5 μM calpeptin for 24 h. Cleaved caspase 3, WFS2 and actin levels were monitored by immunoblotting (Left) and quantified (Right) (n = 3, *P < 0.05). (D, Left)
CAPNS1, WFS2, and actin levels were assessed by immunoblotting in HEK293 cells transfected with empty expression plasmid (Mock), WFS2 expression plasmid,
scrambled siRNA (siCON), or WFS2 siRNA (siWFS2). (D, Right) Protein levels of CAPNS1 are quantified (n = 5, *P < 0.05). (E) HEK293 cells were transfected with empty
(Mock) or WFS2 expression plasmid, and then treated with MG132 (2 μM) or untreated (UT). Expression levels of CAPNS1 and WFS2 were measured by immuno-
blotting (Left) and quantified (Right) (n = 4, *P < 0.05). (F) HEK293 cells were transfected with empty orWFS2 expression plasmid, and then treatedwith cycloheximide
(100 μM) for indicated times. (Left) Expression levels of CAPNS1 and actin were measured by immunoblotting. (Right) Band intensities corresponding to CAPNS1 in Left
were quantified by Image J and plotted as relative rates of the signals at 0 h (n = 3, *P < 0.05). (G) NSC34 cells were transfected with mock empty vector, FLAG tagged
ubiquitin (Ub-FLAG) plasmid or cotransfected withWFS2 expression plasmid and Ub-FLAG plasmid. Cell lysates were immunoprecipitated with FLAG affinity beads and
analyzed for ubiquitin conjugated proteins by immunoblotting. Levels of CAPNS1 and Ub-FLAG protein were measured in the precipitates. WFS2, CAPNS1 and actin
expression was monitored in the input samples. (H) Brain lysates from control and WFS2 knockout mice were analyzed by immunoblotting. Protein levels of cleaved
spectrin and CAPNS1 were determined (Left) and quantified (Center and Right) (each group n = 3, *P < 0.05).
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calpain activation and cell death in WFS1-knockdown NSC34 cells
(Fig. 6E). To verify these observations in patient cells, we pre-
treated neural progenitor cells derived from iPSCs of a Wolfram
syndrome patient and an unaffected parent with dantrolene, and
then challenged these cells with thapisgargin. Thapsigargin-induced
cell death was increased in neural progenitor cells derived from the
Wolfram syndrome patient relative to those derived from the un-
affected parent, and dantrolene could prevent cell death in the
patient iPSC-derived neural progenitor cells (Fig. 6F). In addition,
we treated brain-specific WFS1 knockout mice with dantrolene
and observed evidence of suppressed calpain activation in brain
lysates from these mice (Fig. 6G). Collectively, these results argue
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that dantrolene could prevent cell death in Wolfram syndrome by
suppressing calpain activation.
Discussion
Growing evidence indicates that ER dysfunction triggers a range
of human chronic diseases, including diabetes, atherosclerosis,
inflammatory bowel disease, and neurodegenerative diseases
(3, 4, 37–39). However, currently there is no effective therapy
targeting the ER for such diseases due to the lack of clear un-
derstanding of the ER’s contribution to the pathogenesis of
these diseases. Although Wolfram syndrome is a rare disease and
therefore not a focus of drug discovery efforts, the homogeneity
of the patient population and disease mechanism has enabled us
to identify a potential target, a calcium-dependent protease,
calpain. Our results provide new insights into how the pathways
leading to calpain activation cause β cell death and neuro-
degeneration, which are schematically summarized in Fig. 6H.
There are two causative genes for Wolfram syndrome, WFS1
and WFS2. The functions of WFS1 have been extensively studied
in pancreatic β cells. It has been shown that WFS1-deficient
pancreatic β cells have high baseline ER stress levels and im-
paired insulin synthesis and secretion. Thus, WFS1-deficient β
cells are susceptible to ER stress mediated cell death (5, 6, 32,
40–42). The functions of WFS2 are still not clear. There is evi-
dence showing that impairment of WFS2 function can cause
neural atrophy, muscular atrophy, and accelerate aging in mice
(14). WFS2 has also been shown to be involved in autophagy (43).
However, although patients with both genetic types of Wolfram
syndrome suffer from the same disease manifestations, it was not
clear if a common molecular pathway was altered in these
patients. Our study has demonstrated, to our knowledge for the
first time, that calpain hyperactivation is the common molecular
pathway altered in patients with Wolfram syndrome. The mech-
anisms of calpain hyperactivation are different in the two genetic
types of Wolfram syndrome. WFS1 mutations cause calpain ac-
tivation by increasing cytosolic calcium levels, whereas WFS2
mutations lead to calpain activation due to impaired calpain
inhibition.
Previously, Wolfram syndrome studies focused on pancreatic
β cell function (5, 40, 41). However, patients also suffer from
neuronal manifestations. MRI scans of Wolfram syndrome pa-
tients showed atrophy in brain tissue implying neurodegeneration
in patients (7, 10). To investigate the mechanisms of neuro-
degeneration in Wolfram syndrome human cells, we established
Wolfram syndrome iPSC-derived neural progenitor lines and
confirmed the observations found in rodent cells and animal
models of Wolfram syndrome. Differentiation of these iPSC-
derived neural progenitor cells into specific types of neurons
should be carried out in the future to better understand which
cell types are damaged in Wolfram syndrome; this will lead to
a better understanding of the molecular basis of this disease and
provide cell models for future drug development.
Calpain activation has been found to be associated with type 2
diabetes and various neuronal diseases including Alzheimers,
traumatic brain injury and cerebral ischemia, suggesting that
regulation of calpains is crucial for cellular health (23). We
discovered that calpain inhibitor III could confer protection
against thapsigargin mediated cell death (Fig. 6A). Our data also
demonstrates that calpeptin treatment was beneficial for cells
with impaired WFS2 function. These results suggest that tar-
geting calpain could be a novel therapeutic strategy for Wolfram
syndrome. However, calpain is also an essential molecule for cell
survival (44). Controlling calpain activation level is a double-
bladed sword. We should carefully monitor calpain functions in
treating patients with Wolfram syndrome (44).
Calpain activation is tightly regulated by cytosolic calcium lev-
els. In other syndromes that increase cytosolic calcium level in
pancreatic β cells, patients experience a transient or permanent
period of hyperinsulinaemic hypoglycemia. This hyperinsulinaemic
hypoglycemia can be partially restored by an inhibitor for ATP-
sensitive potassium (KATP) channels or a calcium channel antag-
onist that prevents an increase in cytosolic calcium levels (45, 46).
Although patients with Wolfram syndrome do not experience
a period of hyperinsulinaemic hypoglycemia, small molecule
compounds capable of altering cellular calcium levels may prevent
calpain 2 activation and hold promise for treating patients with
Wolfram syndrome. Treatment of WFS1-knockdown cells with
dantrolene and ryanodine could prevent cell death mediated by
WFS1 knockdown. Dantrolene is a muscle relaxant drug pre-
scribed for multiple sclerosis, cerebral palsy or malignant hyper-
thermia (47). Dantrolene inhibits the ryanodine receptors and
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fibroblasts of a patient 1610. (A, Right) Karyotype of the Wolfram iPS cells. (B)
Alkaline phosphatase staining of the Wolfram iPS cells. (C–F) Wolfram syn-
drome iPS cells stained with pluripotent markers: Nanog (C), Sox2 (D), SSEA4
(E), and TRA-1 (F). (G) Immunoblot analysis of cleaved spectrin and actin in
neural progenitor cells derived from Wolfram syndrome patient iPS cells. The
relative levels of the spectrin cleavage product are indicated (Left) and
quantified (Right) (n = 4, *P < 0.05). (H, Left) Quantitative analysis of cytosolic
calcium levels in unaffected controls and Wolfram syndrome patients mea-
sured by Fura-2 calcium indicator (All values are means ± SEM; experiment was
performed six independent times with >3 wells per sample each time; n = 6,
*P < 0.05). (H, Right) Quantification of cytosolic calcium levels in unaffected
controls and Wolfram syndrome patients measured by Fluo-4 calcium assay
(experiment was performed four independent times; n = 4, *P < 0.05).
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reduces calcium leakage from the ER to cytosol, lowering cytosolic
calcium level. The protective effect of dantrolene treatment on
WFS1-deficient cells suggests that dysregulated cellular calcium
homeostasis plays a role in the disease progression of Wolfram
syndrome. In addition, it has been shown that stabilizing ER cal-
cium channel function could prevent the progression of neuro-
degeneration in a mouse model of Alzheimer’s disease (48).
Therefore, modulating calcium levels may be an effective way to
treat Wolfram syndrome or other ER diseases.
Dantrolene treatment did not block cell death mediated by
WFS2 knockdown, suggesting that WFS2 does not directly affect
the ER calcium homeostasis (Fig. S4 D and E). RNAi-mediated
WFS1 knockdown in HEK293 cells significantly reduced the
activation levels of sarco/endoplasmic reticulum calcium trans-
port ATPase (SERCA), indicating that WFS1 may play a role in
the modulation of SERCA activation and ER calcium levels (Fig.
S5). It has been shown that WFS1 interacts with the Na+/K+
ATPase β1 subunit and the expression of WFS1 parallels that of
Na+/K+ ATPase β1 subunit in a variety of settings, suggesting that
WFS1 may function as an ion channel or regulator of existing
channels (42). Further studies on this topic would be necessary to
completely understand the etiology of Wolfram syndrome.
Our study reveals that dantrolene can prevent ER stress-
mediated cell death in human and rodent cell models as well as
mouse models of Wolfram syndrome. Thus, dantrolene and
other drugs that regulate ER calcium homeostasis could be used
to delay the progression of Wolfram syndrome and other dis-
eases associated with ER dysfunction, including type 1 and type
2 diabetes.
Materials and Methods
Human Subjects. Wolfram syndrome patients were recruited through the
Washington University Wolfram Syndrome International Registry website
(wolframsyndrome.dom.wustl.edu). The clinic protocol was approved by the
Washington University Human Research Protection Office and all subjects
provided informed consent if adults and assent with consent by parents if
minor children (IRB ID 201107067 and 201104010).
Animal Experiments. WFS1 brain-specific knockout mice were generated by
breeding the Nestin-Cre transgenic mice (Jackson Laboratory) with WFS1
floxed mice (40). WFS2 whole body knockout mice are purchased from MRC
Harwell. All animal experiments were performed according to procedures
approved by the Institutional Animal Care and Use Committee at the
Washington University School of Medicine (A-3381-01).
Calcium Levels. Calcium levels in cells were measured by Fura-2 AM dye and
Fluo-4 AM dye (Life Technology) Inifinite M1000 (Tecan). Cells were plated in
96-well plates at 25,000 cells per well and stained with 4 μg/mL Fura-2 dye
along with 2.5 mM probenecid for 30 min, then the cells were washed with
PBS and kept in the dark for another 30 min to allow cleavage of AM ester.
Fluorescence was measured at excitation wavelength 510 nm and emission
wavelengths 340 nm and 380 nm. Then background subtractions were per-
formed with both emission wavelengths. The subtraction result was used to
calculate 340/380 ratios.
For Fluo-4 AM staining, neural progenitor cells were plated in 24-well
plates at 200,000 cells per well. After staining with Fluo-4 AM dye for 30min
along with 2.5 mM probenecid, cells were washed and resuspended in
PBS. Incubation for a further 30 min was performed to allow complete
deesterification of intracellular AM esters. Then, samples were measured
by flow cytometry at the FACS core facility of Washington University School
of Medicine using a LSRII instrument (BD). The results were analyzed by
FlowJo ver.7.6.3.
Statistical Analysis. Two-tailed t tests were used to compare the two treat-
ments. P values below 0.05 were considered significant. All values are shown
as means ± SD if not stated. Please see SI Materials and Methods for
complete details.
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SI Materials and Methods
Reagents. Thapsigargin, tunicamycin, calpeptin dantrolene, rya-
nodine, and cycloheximide were obtained from SIGMA. RPMI-
1640 and DMEM were from Invitrogen. Neural induction media,
neural proliferation media were from Stemcell Technologies.
MitoProbeDilC1(5) mitochondrial membrane potential assay kit,
Annexin V Alexa Flour488 conjugate, Fluo-4, and Fura-2 calcium
indicators were obtained from Invitrogen. Caspase-glo 3/7 pro-
tease assay kit and calpain-glo protease assay kit was purchased
from Promega. Mito Stress test kit was from Seahorse Bioscience.
Anti-WFS2 antibody, and anti-WFS1 antibody were purchased
from Proteintech, anti-Caspase 3, anti-CAPN2 antibodies were
obtained from Cell Signaling Technology, anti-CAPNS1 and anti-
alpha II spectrin antibody were obtained from Millipore. Anti-
actin antibody was purchased from SIGMA. Anti-Myelin basic
protein antibody was from Santa Cruz Biotechnology. Anti-
Calpain 2 antibody, which detects both CAPN2 and CAPNS1, was
raised in rabbits against bacterially expressed rat calpain 2.
Plasmids and siRNA. pCMV-SPORT6-WFS2 expression plasmid
was purchased from Open Biosystems. pDsRed2-ER vector was
purchased from Clontech. FLAG-tagged WFS2 plasmids were
constructed by inserting FLAG sequences into the N and C termini
of the expression plasmid. GST-WFS2 plasmid was generated by
inserting WFS2 sequence into pEBG mammalian expression plas-
mid. A CAPN2 expression plasmid was generated in pLenti-CMV-
puro plasmid provided by E. Campeau (1). Lipofectamine2000
(Invitrogen) was used to transfect small interfering RNA (siRNA)
directed against WFS2 and CAPN2 into cells. siRNAs were de-
signed and synthesized at QIAGEN as follows: mouse WFS2 CA-
ACAGAAGGAUAGCUUG, human WFS2 CGAAAGUAGU-
GAAUGAAA, human CAPN2 CCGAGGAGGUUGAAAGUA,
rat WFS1 GUUUGACCGCUACAAGUUU. Cells were incubated
in media overnight after siRNA transfection, and then additional
treatments were performed, including ER stress induction.
Cell Culture. Neuro-2a, NSC34, HEK293, MEFs, and COS7 cells
were cultured in DMEM containing 10% (vol/vol) FBS and pen-
icillin and streptomycin. MIN6 cells were grown in DMEM con-
taining 15% FBS and penicillin and streptomycin. INS-1 832/13
cells were cultured in RPMI containing 10% FBS before mea-
surement. Neural progenitor cells were maintained in STEMdiff
Neural Progenitor Medium from Stemcell Technologies.
iPS Cell and Neural Progenitor Cell Generation. To generate iPS
cells, we obtained fibroblasts from nonaffected controls and
patients with Wolfram syndrome. Integration-free iPS cells were
generated via Sendai viral delivery of the four reprogramming
factors, Oct4, Sox2, Klf4, and c-Myc using Life Technologies’
Cytotune reagents and protocol. All WFS- and control-iPSCs
showed silencing of the four transgenes, exhibited characteristic
human embryonic stem cell morphology, expressed pluripotency
markers including ALP, NANOG, SOX2, SSEA4, and TRA-1-
81, and had a normal karyotype. To generate neural progenitor
cells, iPSCs were counted and plated ∼50,000 per well in a 96-
well plate to form uniform embryoid bodies. After 5 d, embryoid
bodies were suspended in neural induction media and replated as
adherent cultures. Fresh media were applied every day for 7 d.
Neural rosettes formed in these cultures were selected and plated.
Plated rosettes were fed with neural induction media every day for
4–7 d to obtain neural progenitor cells.
MALDI-TOFMass Spectrometry.HEK293 cells were transfected with
GST-WFS2 plasmid and empty GST plasmid. Cell lysates were
collected and immunoprecipitated with glutathione beads in lysis
buffer (150 mM NaCl, 0.5% Triton X-100, 50 mM Hepes, 1 mM
EDTA, 1 mMDTT, pH 7.5). The precipitated proteins from both
samples were resolved by SDS/PAGE and stained with Coomassie
blue staining. The distinct bands that only appear in GST-WFS2
lane but not GST lane were analyzed by MALDI-TOF tandem
mass spectrometry on a Shimadzu Axima TOF2 mass spec-
trometry at University of Massachusetts Medical School Pro-
teomics and mass spectrometry facility.
Immunostaining. Cells were fixed in 4% paraformaldehyde for
30 min at room temperature and then permeabilized with 0.1%
Triton X-100 for 2 min. The fixed cells were washed with PBS/
Tween 0.1%, blocked with Image-It FX signal enhancer (Invi-
trogen) for 1 h, and incubated in primary antibody overnight at
4 °C. The cells were washed three times in PBS/Tween 0.1% and
incubated with secondary antibody for 1 h at room temperature.
Images were obtained with a Zeiss LSM 5 PASCAL confocal
microscope with LSM Image software.
FACS Analyses. For flow cytometry analyses, neural progenitor cells
or NSC34 cells were plated in 24-well plates. After staining, cells
were washed and resuspended in PBS. Flow cytometry analyses
were performed with LSRII (BD) at the FACS core facility of
Washington University School of Medicine. The results were an-
alyzed by FlowJo ver.7.6.3.
Quantitative Real-Time PCR. Total RNA was extracted by RNeasy
kits (Qiagen). Reverse transcriptase PCR was performed using
High capacity reverse transcription kit (Applied Biosystems) and
quantitative PCR was demonstrated with Applied Biosystems
ViiA7 using SYBR green dye.
2D Fluorescence Difference Gel Electrophoresis.Proteins were extracted
from cerebellums from WFS1 knockout mice and control mice.
Equal amount of protein extract from paired samples were labeled
by CyDye DIGE fluors. The spectrally resolvable dyes enabled si-
multaneous coseparation and analysis of samples on a single mul-
tiplexed gel. These paired samples were simultaneously separated on
a single 2D gel, using isoelectric focusing (IEF) in the first dimension
and SDS polyacrylamide gel electrophoresis (SDS/PAGE) in the
second dimension. After electrophoresis, the gel was scanned using
a Typhoon image scanner. Each scan revealed one of the CyDye
signals (Cy3 and Cy5). ImageQuant software was used to generate
the image presentation data including the single and overlay images.
The comparative analysis of all spots was done by the DeCyder
analysis software. The protein expression ratios between WFS1
knockout and control mice were generated, and differentially
expressed spots were analyzed by MALDI-TOF mass spectrometry.
SERCA Activity Assay. The SERCA activity assay was performed as
described in ref. 2. HEK293 cells were homogenized in hypotonic
buffer, consisting of 10 mM NaHCO3, 250 mM sucrose, 5 mM
NaN3, and 0.1 mM PMSF. ER fractions were isolated using dif-
ferential centrifugation. 125–300 μg of ER protein fractions were
added to the assay mixture [100 mM KCL, 30 mM imidazole-
histidine (pH 6.8), 5 mM MgCl2, 5 mM ATP, 5 mM (COOK)2,
5 mM NaN3, and 50 μM CaCl2 (10 μCi/μmol[45Ca]; CaCl2 Ameri-
can Radiolabeled Chemicals)] heated to 37 °C for 15 min. (The
amount of protein we used in this study was 125 μg per sample). The
reaction was stopped by the addition of 250 mM KCl and 1 mM
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LaCl3. The mix was then vacuum filtered through a 0.2-μm HT
Tuffryn membrane (Sigma). SERCA-dependent calcium transport
was measured by comparing calcium transport in the presence or
absence of 10 μM thapsigargin, a SERCA inhibitor.
1. Campeau E, et al. (2009) A versatile viral system for expression and depletion of pro-
teins in mammalian cells. PLoS ONE 4(8):e6529.
2. Funai K, et al. (2013) Muscle lipogenesis balances insulin sensitivity and strength
through calcium signaling. J Clin Invest 123(3):1229–1240.
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Fig. S1. FLAG-tagged WFS2 was immunoprecipitated from HEK293 cells transfected with WFS2 expression plasmids with either an N-terminal (A) or a
C-terminal FLAG-tag (B), and the immunoprecipitates were analyzed for CAPN2 by immunoblotting with anti-CAPN2 antibody. (C) Cells were fractionated into
cytosolic and ER fractions. Localization of CAPN2 and IRE1 were determined by immunoblotting.
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Fig. S2. MIN6 cells were transfected with control scrambled siRNA (Cont) or siRNA directed against WFS2, and then treated with 0.5 μM thapsigargin (TG) for
6 h or untreated (UT). Expression levels of cleaved caspase 3, WFS2, and actin were measured by immunoblotting (Left). (Right) Quantification of cleaved
caspase 3 is indicated (n = 3, *P < 0.05).
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Fig. S3. (A) MIN6 cells were transfected with scrambled siRNA (Cont) or WFS2 siRNA. Thirty-six h after transfection, cells were treated with or without 100 μM
calpeptin for 12 h. Cleaved caspase 3, WFS2, and actin levels were monitored by immunoblotting. (B) CAPN2, WFS2 and actin levels were assessed by immuno-
blotting in HEK293 cells transfected with scrambled siRNA (siCON), WFS2 siRNA (siWFS2), empty expression plasmid (Mock), or WFS2 expression plasmid (WFS2).
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Fig. S4. INS-1 832/13 (A) and NSC34 (B) cells were pretreated with or without 10 μM dantrolene for 24 h. Cytoplasmic calcium levels were measured by Fura-2
calcium indicator over a period. Thapsigargin was added at 0 min time point (n = 6, the experiment was repeated six independent times). (C) INS-1 832/13 cells
were transfected with scrambled siRNA (Cont) or WFS1 siRNA. Twenty-four h after transfection, cells were treated with or without 2 μM ryanodine for 24 h.
Cleaved caspase 3, WFS1, and GAPDH levels were monitored by immunoblotting (Left) and quantified (Right) (n = 3, *P < 0.05). (D and E) INS-1 832/13 cells (D)
and NSC34 cells (E) were transfected with scrambled siRNA (Cont) and WFS2 siRNA. Twenty-four h after transfection, cells were treated with or without 10 μM
dantrolene for 24 h. Cleaved caspase 3, WFS2 and GAPDH levels were monitored by immunoblotting. Quantification of cleaved caspase 3 protein levels are
shown to the right (n = 3, *P < 0.05).
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Fig. S5. (A) SERCA activity was measured in HEK293 cells stably expressing shRNA directed WFS1 or a scrambled sequence (Control). All values are means ±
SEM. For the wild-type condition, n = 6; the experiment was repeated six independent times. For the WFS1 knockdown condition, n = 7; the experiment was
repeated seven independent times. *P < 0.05. (B) Protein levels of WFS1 and actin were monitored in HEK293 cells stably expressing shRNA directed against
WFS1 or a scrambled shRNA (Control). Quantification is shown on the right (n = 3, *P < 0.05).
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Table S1. GST-WFS2 interacting proteins
Order on gel Gene symbol Full name Molecular weight, KDa
1 PRKDC DNA dependent protein kinase catalytic subunit 450
2 COPA Coatomer Subunit alpha 140
3 IPO7, 4, 9 Importin 7, 4, and 9 120
4 XPO1, 2 Exportin 1, 2 110
5 MMS19 MMS19 nucleotide excision repair 110
6 CNX Calnexinp 67
7 CAPN2 calpain-2 80
8 GRP78 GRP78 78
9 TUBA TUBB Alpha and Beta Tubulin 50
Table S2. Information on genotypes and phenotypes of Wolfram syndrome and control subjects
iPSC line Source
Clinical
diagnosis
WFS1
mutation Sex
Age at
biopsy
Age at onset
of DM
Age at onset
of OA Deafness DI
Wolf-2010–5 Washington University
Wolfram Clinic
WFS H313Y F 15 3.8 12 1.7 NA
Wolf-2010–9 Washington University
Wolfram Clinic
WFS A126T; W613X M 16 10.8 11 NA 14
Wolf-2010–11 Washington University
Wolfram Clinic
WFS A126T; W613X M 10 7.5 6 8 10
Wolf-2010–13 Washington University
Wolfram Clinic
WFS L200fs286Stop;
E752Stop
F 7 4.8 5.2 6 7.5
GM01610 Corriell Research
Institute
WFS W648X; G695V F 11 NA NA NA NA
BJ CRL-2522 ATCC Control NA M Newborn NA NA NA NA
Wolf-2010–5-MO Washington University
Wolfram Clinic
Control None identified F 41 NA NA No No
Wolf-2010–9 MO Washington University
Wolfram Clinic
Control NA F 33 NA NA No No
Wolf-2012–13-FA Washington University
Wolfram Clinic
Control NA M 42 NA NA No No
WFS, Wolfram syndrome; DM, diabetes mellitus; OA, optic atrophy; DI, diabetes insipidus.
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Table S3. Chemical compounds used for a screen targeting the ER calcium homeostasis
Drugs Treatment conc.
1 Nicotinamide(Vitamin B3) 10 μM
2 Valproic acid 10 μM
3 Sodium tauroursodeoxycholate(TUDCA) 10 μM
4 (-)-Riboflavin(Vitamin B2,Vitamin G) 10 μM
5 Thiamine hydrochloride(Vitamin B1 hydrochloride) 10 μM
6 Memantine hydrochloride 10 μM
7 (+-)-a-Lipoic acid 10 μM
8 Kynurenic acid 10 μM
9 Folic acid 10 μM
10 Idebenone 10 μM
11 Acetovanillone(Apocynin) 10 μM
12 Aspirin 10 μM
13 Pyridoxine hydrochloride 10 μM
14 Dextromethorphan hydrobromide 10 μM
15 2.3-Pyridinedicarboxylic acid(DPA) 10 μM
16 R-(-)-Deprenyl hydrochloride(Selegiline hydrochloride) 10 μM
17 NS-398 10 μM
18 4-Aminobenzoic acid(PABA,Vitamin Bx, Vitamin H1) 10 μM
19 Biotin 10 μM
20 D-Pantothenic acid hemicalcium salt(Vitamin B5) 10 μM
21 Chondroitin sulfate A sodium salt from bovine tracha(Glycosaminoglycans) 10 μg/mL
22 Ebselen 10 μM
23 PPBP maleate(4-PPBP maleate) 10 μM
24 Minocycline hydrochloride 10 μM
25 Pravastatin sodium salt hydrate 10 μM
26 N-tert-Butyl-alpha-phenylnitrine(PBN) 10 μM
27 Curcumin 10 μM
28 TRO19622(Olesoxime) 10 μM
29 Pyridoxamine dihydrochloride 10 μM
30 Pyridoxal hydrochloride 10 μM
31 Fibroblast Growth factor-Basic human 100 ng/mL
32 Bryostatin1 100 nM
33 Brain derived neurotrophic factor human 100 ng/mL
34 SRP4988(PEDF) 100 ng/mL
35 Erythropoietin 0.1 UN/mL
36 Clioquinol 10 μM
37 Kenpaullone 10 μM
38 PARP inhibitor iii,DPQ 10 μM
39 Glial Cell Line-derived Neurotrophic Factor human 100 ng/mL
40 Ciliary Neurotrophic Factor, human 100 ng/mL
41 Nitric Oxide Synthase, Neuronal Inhibitor 1(nNOS inhibitor) 10 μM
42 Riluzole 10 μM
43 Creatine 10 μM
44 Anisomycin from streptomyces griseolus 10 μM
45 NE 100 hydrochloride 10 μM
46 Phenytoin 10 μM
47 CsA 300 nM
48 FK506 300 nM
49 Rapamycin 10 μM
50 Docosahexaenoic acid 10 μM
51 GLP-1 50 nM
52 Diazoxide 300 μM
53 Glibenclamide 100 μM
54 2-APB (2-Aminoethoxydiphenyl borate) 200 nM
55 IL1RA 100 ng/mL
56 Retinol 10 μM
57 GW5015-16 10 μM
58 GW9508 10 μM
59 Etomoxir 20 μM
60 Verapamil 20 μM
61 Metformin 44 μM
62 AICAR 10 μM
63 pioglitazone 10 μM
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Table S3. Cont.
Drugs Treatment conc.
64 Troglitazone 10 μM
65 N-Acetyl D-Shingosine 10 μM
66 Dihydroceramide C2 10 μM
67 Fumonisin B1 10 μM
68 Ros inhibitor 100 μM
69 SNAP 1 mM
70 Dantrolene 10 μM
71 Bcl XLBH4 human 1 μM
72 Calp. Inhibitor iii 1 μM
73 salburinal 25 μM
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